Manager TitleAgeSince
Director of Finance/CFO 62 01/03/2017
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 50 21/11/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.61% - - 40Cr
+1.16%-1.13%-18.25%+9.38% 18TCr
+0.02%+4.24%-19.55%+15.88% 12TCr
-1.22%+0.70%+1.86%+32.59% 12TCr
+2.29%+17.36%-42.18%+8.22% 9.33TCr
-2.21%-2.91%-0.51%+75.12% 6.32TCr
-1.06%+1.75%+13.48%+74.12% 5.57TCr
-0.75%+3.73%+7.04%-23.26% 5.42TCr
-1.13%+0.00%-12.56%+30.09% 4.41TCr
+0.17%+5.85%-5.20%-11.43% 3.4TCr
Average -0.27%+3.30%-8.43%+23.41% 7.59TCr
Weighted average by Cap. -0.00%+3.09%-11.77%+21.99%

Financials

2017 2018
Net sales 2.02Cr 1.8Cr 1.66Cr 1.51Cr 2.82Cr 191.32Cr 2.87Cr 20Cr 7.92Cr 100.24Cr 7.56Cr 7.4Cr 316.03Cr 2.77Cr 2.47Cr 2.28Cr 2.07Cr 3.87Cr 262.69Cr 3.93Cr 27Cr 11Cr 137.63Cr 10Cr 10Cr 433.91Cr
Net income -2.13Cr -1.9Cr -1.76Cr -1.59Cr -2.98Cr -201.98Cr -3.03Cr -21Cr -8.36Cr -105.82Cr -7.99Cr -7.82Cr -333.64Cr -2.51Cr -2.24Cr -2.07Cr -1.88Cr -3.51Cr -238.48Cr -3.57Cr -25Cr -9.87Cr -124.95Cr -9.43Cr -9.23Cr -393.93Cr
Net Debt - -
Logo Avedro, Inc.
Avedro Inc is a United States-based company. The Company is an ophthalmic pharmaceutical and medical device company developing and commercializing a suite of products based on its corneal collagen cross-linking technology platform to address a wide variety of ophthalmic disorders and conditions, primarily associated with corneal weakness. Its primary components of the Avedro Cross-Linking Platform are pharmaceutical formulations of riboflavin (vitamin B2), a ‘single dose pharmaceutical,’ sold primarily in conjunction with the Company’s innovative devices for the delivery of metered doses of ultraviolet (UVA) light, a medical device.
Employees
-
  1. Stock Market
  2. Stocks
  3. AVDR Stock